Taro Pharmaceutical industries | Sustainability Performance
Develops, manufactures, and markets pharmaceutical products. Provides R&D, production, and operational support. Supports regulatory compliance, quality assurance, and distribution of healthcare and medical products.
1950
Israel
1,001 - 5,000 employees
Pharmaceuticals
$500M - 1B in revenue
$25M - 100M in profitability
Sustainability Ranking & Industry Benchmark
#6852
Overall#22
in Israel#156
in PharmaceuticalsSustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Controversy level
Powered by illuminem
Market cap
Revenue
EBITDA
Operating margin
P/E ratio
Revenue & EBITDA
$629.0MFY2024 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Revenue by region
Revenue by region %
CANADA
Canada and Cayman islands.
ISRAEL
Other Country.
United States [Member]
Powered by illuminem
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
R&D intensity
10.2%FY2024
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
3.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.6
▼ 2.7%
0.6
▼ 2.7%
0.6
▼ 0.2%
0.7
2025Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Available
Recycling policy
Not available
Workplace health & safety policy
Available
33%
Independent Directors
3 out of 9 incl. management
Overall score
33
Environment
4
Social
67
Governance
29
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Not available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
